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LeukemiaAbstract Background: Ankaferd Blood Stopper (ABS) is a preparation of plant extracts origi-
nally used as a hemostatic agent. It has pleiotropic effects in many cellular processes such as cell
cycle regulation, apoptosis, angiogenesis, signal transduction, inﬂammation, immunologic processes
and metabolic pathways as well as hemostatic activity. This unique preparation has been widely
investigated for its properties. However there are no studies investigating its action on leukemic
cells.
Aim: Aim of the study was to examine the ABS action on PAR1 and EPCR in leukemia cells.
However, during the experiments, we observed the apoptotic effect of ABS on leukemic cells, par-
ticularly Jurkat cells. As a result the mechanism of apoptosis induced by ABS treatment was also
explored in the study.
Material and method: Two leukemia cell lines, K-562 and Jurkat, were utilized for the study.
Expression analyses of PAR1, EPCR and p21 upon ABS treatment were performed by quantitative
real time PCR. Annexin V method was used for apoptosis detection.
Results: Our results demonstrated that ABS alters PAR1 and EPCR expression in K-562 and
Jurkat cells in a time and dose dependent manner. Additionally it was found that ABS treatment
induces apoptosis in leukemia cells. Possible involvement of PAR1 and p21 in this apoptotic process
was observed in Jurkat cells.
Conclusion: This study concludes that depending on the concentration and duration of the appli-
cation, ABS causes apoptosis by regulating PAR1 and p53-independent p21 involvement in
20 M. Mumcuoglu et al.apoptosis stimulation in leukemia cells. The composition of ABS plant extracts might be responsi-
ble from the apoptotic effect that was observed. We think that our results could contribute to the
development of new treatment for leukemia therapy.
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Ankaferd Blood Stopper (ABS) is a preparation of plant
extracts composed of Thymus vulgaris, Glycyrrhiza glabra,
Vitis vinifera, Alpinia ofﬁcinarum, and Urtica dioica. Each of
these plants has some effects on the endothelium, blood cells,
angiogenesis, cell proliferation and cell mediators [1–5]. ABS
originally was known for its hemostatic activity. ABS achieves
this effect by inducing the formation of a protein network
which includes interactions between ABS and blood proteins,
especially with ﬁbrinogen-gamma. Protein agglutination and
erythroid aggregation are important components of ABS-
induced protein network. Spectrin, ankyrin and actin are vital
proteins that are modulated by ABS during erythroid aggrega-
tion process [1,40]. ABS also upregulates the level of diverse
types of proteins and factors acting on cellular functions such
as protein-2 (AP2), androgen receptor (AR), cyclic AMP
response element or activating transcription factor-1 (CRE-
ATF1), cyclic AMP response element binding protein (CREB),
E2F1–5, E2F6, EGR, interferon (IFN)-stimulated response
element (ISRE), Myc-Max, nuclear factor-1(NF-1), protein-
53 (p53), SMAD2/3, peroxisome proliferator-activated recep-
tor (PPAR) and Yin-Yang (YY1). These factors play a role
in various cellular mechanisms, such as cell cycle regulation,
apoptosis, angiogenesis, signal transduction, inﬂammation,
immunologic processes and metabolic pathways [1].
Endothelial cell protein C receptor (EPCR) is a member of
activated protein C anticoagulant pathway. EPCR shows
equal afﬁnity to protein C and activated protein C (APC)
[6]. EPCR function has not been fully understood in different
cell types where EPCR is known to be expressed, such as
hematopoietic cells and cerebral smooth muscle cells. PAR1
is a member of proteinase-activated receptor (PARs) family
that is found in seven transmembrane G-protein-coupled
receptors group [7]. Activated PAR1 mediates intracellular sig-
naling by coupling G proteins and by using different second
messenger systems [8]. Besides its widely accepted role in plate-
let aggregation and hemostasis, PAR1 has different effects in
other physiological functions such as inﬂammation, Ca (2+)
dependent Cl () segregation in intestinal epithelial cells, reg-
ulation of vascular dynamics, and apoptosis [9–12]. PAR1
involvement in apoptotic process has been shown in neurons,
intestinal epithelium and different types of cancer cells by sev-
eral studies [13–16].
Cell cycle progression is controlled by subsequent activa-
tion of cyclin/Cdk complexes. Cyclin dependent kinase inhibi-
tors (CKIs) block the activity of cyclin/Cdk complexes and
inhibit cell cycle progression. Overexpression of p21 (Waf1/
Cip1), one of the cyclin dependent kinase inhibitors, has an
important role in cell cycle arrest and apoptosis [17].
ABS has pleiotropic effects on many types of cells and
physiological systems. ABS action on PAR1 and EPCR hasbeen explored in the HUVEC model. These studies shown
ABS mediates dose and time dependent, reversible action on
PAR1 and EPCR expression in HUVEC cells [18,19]. But to
the best of our knowledge, there are no studies investigating
the ABS action on PAR1 and EPCR in hematologic malignan-
cies. For this purpose, ﬁrst we designed a study to analyze the
effect of ABS on EPCR and PAR1 in leukemia cells; K-562
and Jurkat cell lines, in different concentrations and at differ-
ent time points. During the experiments we found that ABS
induces apoptosis particularly in Jurkat cells. We then
expanded our study to clarify the mechanism of apoptosis
induced by ABS and analyzed critical genes in apoptotic path-
ways such as p21, bcl-2 and bax.
2. Materials and methods
2.1. Ingredients of Ankaferd Blood Stopper (ABS)
An ampoule form of ABS was used in the experiments.
Amount of active substances in ampoule form of ABS is as fol-
lows: T. vulgaris (0.05 mg/ml), G. glabra (0.09 mg/ml), V. vinif-
era (0.08 mg/ml), A. ofﬁcinarum (0.07 mg/ml), and U. dioica
(0.06 mg/ml) [1].
2.2. Cell culture and Ankaferd treatments
Leukemic cell lines, K-562 and Jurkat, were grown in RPMI
medium (Lonza, Belgium) supplemented with 20% fetal calf
serum (FCS) (Lonza, Belgium), 50 mg/ml penicillin/streptomy-
cin and 1% L-glutamine (Lonza, Belgium). Each cell line was
maintained in a humidiﬁed incubator at 37 C supplied with
5% CO2. Cell lines are from ATCC.
4 · 106 cells from each cell line were counted and seeded
into 25 cm2 ﬂasks within the 5 ml of growth medium. Then
ABS was applied into the ﬂasks at two different concentra-
tions, 10 ll/ml (high dose) and 1 ll/ml (low dose). Only ddH2O
(pH: 2), which is similar in pH to ABS, was added to the con-
trol ﬂasks. After incubation with ABS at time periods of
20 min, 30 min, 45 min, 1 h, 6 h and 24 h experiments were
stopped by removing the ABS containing medium. Cells were
washed once with cold 1· PBS and then pelleted by centrifuga-
tion to isolate RNA.
2.3. RNA isolation and cDNA synthesis
Total RNA isolations were performed in the MagNA Pure
Automated Isolation System (Roche) using MagNA Pure
Compact RNA isolation kit (Roche).
cDNA synthesis was carried out using Transcriptor First
Strand cDNA synthesis kit (Roche) following the manufac-
turer’s instruction.
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Quantitative PCR (qRT-PCR) was performed using PAR1 and
EPCR speciﬁc primers and TagMan hydrolysis probes (respec-
tively Universal Probe Library Probes #17 and #50, Roche
Diagnostics, Germany) on aLight Cycler 480 II system (Roche).
18S was used for the normalization of PAR1 and EPCR. p21
expression analysis was implemented by using Light Cycler
RNAMaster SYBRGreen I kit (Roche) following themanufac-
turer’s instruction. GAPDH was utilized for the normalization
of p21. Primer sequences; PAR-1: F_50-TCAGAA-
GATGCCTCCG GATA-30 R_50- CACAGA TGGGACAAA-
GAGTGTC-30, EPCR: F_50-GTAGCCAAGACGCCT-30
R_50- GATAGGGGTCGCGGA-30, p21: F_50-CGATGGA
ACTTCGACTTTGTCA-30 R_50-GCACAAGGGTACAA-
GACAGTG-30, 18S: F_50- GTAACC CGTTGAAC CCC-
ATT-30 R_50- CCATCCAATCGGTAGTAGCG and GAP
DH: F_50-GGCTGA GAACGGGAAGC TTGTCAT-30
R_50CAGCCTTCTCCATGGTGGTGAAGA-30. Each condi-
tion of quantitative PCR reactions was studied at least two
times. Expression analysis was performed with the Relative
Basic Quantiﬁcation Software, which uses 2DDCt-method, pro-
vided with Light Cycler 480 II.
2.5. Detection of apoptosis
Apoptosis detection was performed using Annexin V apoptosis
detection kit (sc-4252 AK) (Santa Cruz Biotechnology, Inc.) on
live cells according to the manufacturer’s recommendations.
2 · 106 cells were counted and seeded into 25 cm2 ﬂasks.
Cells were then treated with ABS in different concentrations
and at different time points. The cells were collected by centri-
fugation at 1500 rpm for 5 min. Cell pellets were washed twice
with cold PBS and re-suspended in 1· Assay buffer at concen-
tration of 1 · 106 cells/ml. A 100 ll aliquot of the suspension
(containing 1 · 105 cells) was transferred and incubated for
15 min at room temperature with Annexin V-FICT and PI-
rhodamine in dark. Cell suspensions were placed on adhesive
slides and covered with glass coverslips, followed by immediate
observation by ﬂuorescence microscopy and pictures were
taken (Nikon Eclipse 80i).
2.6. Statistical analysis
Statistical analysis of the results was obtained by using Excel-
one way ANOVA (analysis of variance) test. P values of
<0.05 or <0.01 were accepted as statistically signiﬁcant.
3. Results
3.1. EPCR and PAR1 expression are regulated by ABS in a time
and dose dependent manner
To examine whether ABS generates any effect in leukemia
cells, two leukemia cell lines were used, the K-562 cell line
which is derived from a chronic myelogenous leukemia patient
and the Jurkat cell line which is derived from an acute T cell
leukemia patient. Cell lines were treated with ABS in various
concentrations, 10 ll/ml (high dose) and 1 ll/ml (low dose),
and at multiple time points, 20 min, 30 min, 45 min, 1 h, 6 hand 24 h. Then EPCR and PAR1 expressions were analyzed
by quantitative PCR method.
As seen in Fig. 1, we observed that the effect of ABS on
EPCR is dose and time dependent in both cell lines. In both
cell lines, high dose and low dose of ABS affected EPCR
expression differentially.
In K-562 cell line, administration of ABS at a low dose
caused a decrease in EPCR expression at the beginning. This
effect was recovered and passed the control level at 1 h time
point. Then a decrease was observed in the expression level,
and continued until 24 h. Similarly, at high dose, ABS gener-
ated a fast decrease in EPCR expression. Recovery of the
expression was observed at 1 h time point and then sharp
decrease was followed. Another peak was seen at 24 h
(Fig. 1A and B).
In Jurkat cell line, we noticed a similar expression dynamic
as observed in K-562 at low dose of Ankaferd treatment
(Fig. 1C). But high dose Ankaferd treatment interestingly gen-
erated constant decrease in EPCR expression at all of the time
points. This decrease was analyzed by one-way ANOVA test
and found statistically signiﬁcant (p< 0.0001) (Fig. 1D).
Analysis of PAR1 expression upon ABS treatment also
showed, time and dose dependent differential expression pat-
terns in both cell lines (Fig. 2).
In K-562 cells, addition of ABS did not generate any effect
at 20 min time point. But at 30 min at both concentrations,
decrease in PAR1 expression was observed. After this time
point, response to ABS treatment was dissimilar at both con-
centrations. Low dose of ABS produced an expression increase
at 1 h, followed by a decrease at 6 h and an increase at 24 h
time point. Conversely, following a similar decrease at
30 min, high dose ABS produced steadily increasing expression
until 24 h (Fig. 2A and B).
Jurkat cells, showed a different pattern and more pro-
nounced increases were observed in PAR1 expression after
ABS treatment compared to K-562 cells (Fig. 2C and D).
When the low dose of ABS was applied, at the beginning
(20 min) decrease in PAR1 expression was detected. Then
sharp increase (3.5-fold) in PAR1 expression was observed at
30 min. At 1 h the PAR1 expression level decreased to the con-
trol level. Another slight increase was observed at 24 h (1.5-
fold) (Fig. 2C). Similarly high dose of ABS created decrease
in PAR1 expression at 20 min and gradual recovery was seen
at 30 min and 45 min. Then much more intense (14-fold)
increase in PAR1 expression compared to low dose was
observed at 1 h (Fig. 2D). In Jurkat cells, expression changes
at both concentrations of Ankaferd treatment (1 and 10 ll/
ml) were found to be statistically signiﬁcant (p< 0.0001).
3.2. ABS treatment induces apoptosis in leukemia cells
Anti-neoplastic activity of ABS has previously been reported
in osteosarcoma (SAOS-2) and human colon cancer (CaCo-
2) cell lines [20,21]. ABS also plays a role in the regulation
of some factors which are functional in cell cycle regulation
and apoptosis [1]. Additionally, it has been shown that
PAR1, depending of the cell type, may induce or prevent apop-
tosis [12]. In light of this information, during the experiments,
we suspected that ABS may induce apoptosis in our cells as
well. To clarify this, we performed Annexin V staining which
is an established method to detect apoptosis in cells [22].
Figure 1 Analysis of EPCR relative expression by qRT-PCR at multiple time points after application of ABS in K-562 and Jurkat cells.
EPCR expression in K-562 cells (A) after 1 ll/ml (low dose) of ABS treatment, (B) after 10 ll/ml (high dose) of ABS treatment. EPCR
expression in Jurkat cells (C) after 1 ll/ml (low dose) of ABS treatment, (D) after 10 ll/ml (high dose) of ABS treatment. 10 ll/ml ABS
treatment caused signiﬁcant decrease in EPCR expression in Jurkat cells.
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apoptosis detection kit (sc-4252 AK) in both cell lines, K-562
and Jurkat, and at four different time points (20 min, 1 h,
6 h and 24 h). Time points we consider as a critical stages,
judging by changes we observed in PAR1 expression. ABS
was added to the medium and treatments were ﬁnalized by pel-
leting at these four time points. Cells were then labeled with
FITC conjugated Annexing V to detect early stages of apopto-
sis and with PI to detect late apoptosis. Samples were analyzed
immediately after labeling under the ﬂuorescent microscope.
Meanwhile, light microcopy images were taken subsequent to
ﬂuorescent images to visualize cells that were neither stained
by FITC nor by PI.
Annexin V staining showed that in K-562 cells low dose of
ABS triggers apoptosis at 1 h. But at high dose, profoundly
higher apoptosis was observed in 6 and 24 h samples.
In Jurkat cells, low dose of ABS generated the same
amount of apoptosis at all-time points. However at high dose,
6 and 24 h samples showed higher levels of apoptosis as com-
pared to other time points (Fig. 3).
3.3. ABS may induce apoptosis via increasing PAR1 and p21
expression in Jurkat cells
To analyze the apoptotic mechanism generated by ABS
treatment in leukemic cells, critical genes that are located inapoptotic pathways were investigated. Bax, Bcl-2 and p21
genes were analyzed by qRT-PCR at four different time points
(20 min, 1 h, 6 h and 24 h) which were similar in Annexin V
staining [23]. Bax and Bcl-2 expression results did not show
any changes upon ABS treatment (data were not shown).
However, when ABS was applied at different concentrations
and at different time points, p21 expression showed interesting
changes (Fig. 4). In particular, Jurkat cell line exhibited prom-
inent increase in p21 expression (Fig. 4A). In addition we
observed some relationship between PAR1 and p21 expression
pattern at similar time points in both cell lines, but especially
high dose Ankaferd treatment in Jurkat cell line (Figs. 2D–
4A). Addition of high dose of ABS in Jurkat cells produced
high increase in both PAR1 and p21 expressions at 1 h, and
in parallel we observed more apoptotic cells at 6 and 24 h time
points of Annexin V staining at high dose. This ﬁnding sup-
ports the idea that there is a link between increases in PAR1
and p21 expression and apoptosis that was observed in Jurkat
cells (Figs. 2–4).
The effect of ABS on expression changes of PAR1 and p21
was not as strong in K-562 cells. The changes were only one-
fold higher in K-562 cells compared to the control. Low dose
of ABS treatment generated increase in PAR1 expression at
1 h time point. Similarly Annexin V staining showed more
apoptotic cells in 1 h samples at the same concentration. But
there was no similar expression increase in p21. In high dose
Figure 2 Analysis of PAR1 relative expression by qRT-PCR at multiple time points after application of ABS in K-562 and Jurkat cells.
PAR1 expression in K-562 cells (A) after 1 ll/ml (low dose) of ABS treatment, (B) after 10 ll/ml of ABS treatment. PAR1 expression in
Jurkat cells (C) after 1 ll/ml (low dose) of ABS treatment, (D) after 10 ll/ml (high dose) of ABS treatment.
ABS action on PAR1 and EPCR in leukemia cells 23of ABS treatment, we observed parallel results with p21
expression and apoptosis increase but not with PAR1 expres-
sion (Fig. 4).
It could be deduced from all data that the apoptotic process
starts with increase in PAR1 and then p21 expression leading
to apoptosis at 10 ll/ml concentration in Jurkat cells which
is an acute T cell leukemia cell line.
4. Discussion
Apoptosis or programed cell death is an important cellular
protection mechanism which removes the cells that are bearing
mutations, DNA damage or showing aberrant proliferation.
Different types of stresses such as DNA damage, oncogene
expressions, and hypoxia may induce apoptotic signaling path-
ways. One of the major players of these pathways is p53 tumor
suppressor protein [24,25]. Upon activation, by stress stimuli,
p53 induces transcription of its target genes and cells undergo
either, cell cycle arrest or apoptosis. Activation of p21 through
p53 results with cell cycle arrest at the G1 phase [26,27]. But
also it has been shown that transcription of p21 by p53 can
be repressed by Myc during p53-dependent apoptosis [28].
Conversely there are evidences that p21 also stimulates apop-
tosis independently from p53 in different types of stresses
and diverse cellular contexts [29,30]. Another major check-
point of apoptosis process is the ratio of pro-apoptotic(BAX) and anti-apoptotic (BCL-2) members. Caspase path-
way and mitochondrial dysfunction are located downstream
of this checkpoint. Therefore it is important to ﬁnd the
changes of the ratio between these two molecules for the deter-
mination of apoptosis [31,32].
In our study, Annexin V results reveal that ABS treatment
in Jurkat and K-562 cells cause apoptosis at varying degrees.
Apoptosis response was more apparent in Jurkat cells as com-
pared to K-562 cells at both concentration levels. To analyze
the mechanism of apoptosis that we observed in leukemia cell
lines, Bcl-2, Bax and p21 expression levels of these cell lines
were detected by qRT-PCR at both concentrations and differ-
ent time points. Bcl-2 and Bax expression results did not show
any change associated with ABS treatment. However p21
expression changes showed correlations with apoptosis
response. Also another striking result was the concordance
between PAR1 and p21 expression peaks and apoptosis
appearance times. It has been shown that PAR1 can mediate
apoptosis in different cell types such as epithelial and endothe-
lial cells, ﬁbroblasts, neuronal cells and tumor cells by either
inducing or inhibiting this process [12–16,33]. This dual effect
mostly relies on thrombin concentration which is the physio-
logical agonist of PAR1 or other PAR1 activating peptides.
It has been shown that low concentrations of thrombin protect
tumor cell growth whereas high concentrations of thrombin
induce apoptosis [15,33]. Huang et al. demonstrated that in
K562 
1 µl/ml ABS 
Jurkat
10 µl/ml ABS  
20 min
1 µl/ml ABS 
10 µl/ml ABS  
1 h
1 µl/ml ABS  
10 µl/ml ABS  
6 h
1 µl/ml ABS  
10 µl/ml ABS  
24 h
Figure 3 Apoptosis detection by Annexin V staining in K-562 and Jurkat cells after ABS treatment.
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ated apoptosis with the up-regulation of p21 and caspases.
They also showed that p21 induction is mediated by STAT1-
dependent pathway independent from p53 [14]. Our study also
showed that, in acute leukemia cells, 10 ll/ml concentration of
ABS was able to induce apoptosis process via up-regulation of
PAR1 and p21. p53 is mutated in Jurkat cells [34]. Therefore in
Jurkat cells up-regulation of p21 is independent of p53. To
clarify the involvement of thrombin and other components
of the signaling pathway downstream of p21, further analysis
is required.
Anti-neoplastic effect of ABS has been explored in solid
tumor cell lines such as Saos-2, an osteosarcoma cell line and
CaCo-2, a colon cancer cell line [20,21]. In these studies, theyobserved inhibition in cell proliferation and decline in cell
survival as well as loss in their invasion capabilities of these cell
lines especially at 10 ll/ml concentration of ABS treatment. In
our study, we found anti-neoplastic action of ABS in leukemia
cells via apoptosis induction. Apoptosis was more prominent
at 10 ll/ml concentration of ABS in Jurkat cells as also were
observed in CaCo-2 cells.
Our results also reveal that ABS effects EPCR expression in
K-562 and Jurkat cells in a dose and time dependent manner.
ABS addition to the cells (in both cell lines) caused decreasing
and increasing cycles in EPCR expression. In addition, high
dose ABS was able to produce statistically signiﬁcant constant
decrease EPCR expression in Jurkat cell line. These expression
differences could be explained by the molecular and genetic
Figure 4 p21 expression changes in leukemia cells after ABS
treatment. (A) p21 relative expressions in Jurkat cells, (B) p21
relative expressions in K-562 cells.
ABS action on PAR1 and EPCR in leukemia cells 25differences in cell lines. Additionally decreasing and increasing
cycles in EPCR expression in both cell lines were noticeable,
which implies that two different factors are possibly acting at
these time points. This can be a subject of further studies.
Thrombotic complications are frequently seen in hemato-
logical malignancies and solid tumors [35]. Generally, pro-
coagulation factors are thought to be responsible for this
complication.
There have been few studies investigating EPCR expression
in hematological malignancies [36–38]. In these studies they
detected EPCR expression in a wide range of malignant hema-
tological cells. Our study shows EPCR expression in K-562
and Jurkat cells. Time and dose dependent regulation of this
expression upon ABS treatment was noticeable. Previously,
in HUVEC model, ABS actions on EPCR, PAR-1 and PAI-
1 have been investigated where the hemostatic effect of ABS
was found to be correlated with the immediate action of
ABS via increased expression of prohemostatic PAI-1 and
decreased expression of anticoagulant EPCR and PAR-1
[18,19]. Our results were also in parallel with these results,showing that at 10 ll/ml concentration ABS triggers a con-
stant decrease on EPCR expression in acute leukemia cells.
Currently ABS is used for the management of clinical
hemorrhages and wound healing. Hemostatic effect of ABS
has been tested in the clinical trials and found safe and effec-
tive compared to other traditional methods/agents [1,41,42].
Patiroglu et al. used ABS to study its efﬁcacy in oral mucositis
of pediatric patients who were treated for hematologic and
solid organ malignancies [43]. Their study displayed topical
use of ABS in most of these patients causing signiﬁcant regres-
sion in their oral mucositis. Another important point is shown
by this study in patients with leukemia ABS used safely
without causing leukemic cell proliferation.
Red blood cell (RBC)–ﬁbrinogen interaction and the role of
RBCs in the clot formation are very critical hemostatic action
of ABS [1]. These factors should also be considered for the
development of hemostatic agents in the management of
bleeding disorders.
5. Conclusion
Our analyses reveal that ABS responsible for apoptosis
induction in different degrees, depending on the concentration
and duration of the application by regulating PAR1 and
p53-independent p21 involvement in apoptosis stimulation.
Additionally ABS treatment produced dose and time
dependent changes in the EPCR expression in our leukemia
cells.
Disruption of apoptosis generally leads to proliferation of
defective cells which ultimately cause oncogenesis. Therefore
evasion of apoptosis is accepted as one of the main character-
istics of cancer cells [39]. Restoration of deregulated apoptosis
in cancer treatment is proposed as an approach for the devel-
opment of new chemotherapeutics. We think that some of the
plant extracts which compose ABS are responsible from apop-
tosis induction in the leukemia cells. Further investigation
could contribute to ﬁnding new apoptotic drugs which can
be used in leukemia treatment. Also our ﬁndings broaden
our understanding of mechanism PAR1 and p21 activation
and its effect on apoptosis, as well as ABS action on leukemia
cells.
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